IRAK4 Inhibitor Tablet Composition for Dissolution and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing IRAK inhibitor compounds face challenges with poor dissolution, high impurity content, and instability in pharmaceutical formulations.
Innovation Solution
A pharmaceutical composition comprising a compound of formula I, anhydrous calcium hydrogen phosphate, microcrystalline cellulose, sodium dodecyl sulfate, colloidal silicon dioxide, cross-linked sodium carboxymethyl cellulose or starch, and magnesium stearate, optimized for improved dissolution and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the IRAK inhibitor compound is formulated without optimized excipients, then the formulation development is simpler, but the dissolution performance is poor
Solution Approach 1:
The patent introduces specific excipients as intermediaries to mediate between the active ingredient and the dissolution medium. Sodium dodecyl sulfate acts as a surfactant intermediary to enhance wetting and dissolution, while microcrystalline cellulose and anhydrous calcium hydrogen phosphate serve as diluent intermediaries that provide optimal dissolution characteristics. These intermediaries resolve the contradiction by enabling good dissolution performance without complicating the formulation process.
Solution Approach 2:
The patent optimizes the concentrations and ratios of excipients to achieve optimal dissolution performance. By adjusting the parameters of excipient amounts and their combinations, the formulation achieves enhanced dissolution without requiring complex manufacturing processes. This parameter optimization resolves the contradiction between simplicity and performance.
2Stability of the object's composition
If the pharmaceutical formulation uses conventional excipients, then the formulation is more stable, but the impurity content increases
Solution Approach 1:
The patent employs excipients that are effective at lower concentrations and can be easily removed or degraded, reducing impurity accumulation. The selected excipients are used in optimized amounts that provide stability while minimizing residual impurity content in the final product.
Solution Approach 2:
The patent uses a composite excipient system where multiple excipients work synergistically to provide stability while minimizing impurity formation. The combination of surfactant, diluent, and disintegrant creates a composite formulation that achieves both stability and low impurity content through complementary functions.
3Ease of operation
If the compound is administered without optimization, then the dosing process is simpler, but the dissolution and absorption are insufficient
Solution Approach 1:
The patent introduces dissolution-enhancing excipients as intermediaries that facilitate the transition from simple dosing to effective dissolution and absorption. These excipients mediate between the administered dose and the biological system, ensuring adequate dissolution and absorption without complicating the dosing process for the patient.
Data Source
AI summary
An IRAK4 inhibitor composition, a preparation method and use thereof. The composition comprises: (i) a compound of formula I, a stereoisomer, a solvate or a pharmaceutically acceptable salt thereof; (ii) a diluent; (iii) a disintegrant; and (iv) a lubricant. The structure of formula I is shown as follows: